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Fibrosis is a deregulated and uncontrolled 
repair process that recapitulates features of embryonic 
development and normal wound healing. The 
inappropriate repair by connective tissue, characterized by 
an excessive deposition of collagen and other extracellular 
matrix components, is now known as an important feature 
of many chronic diseases, including myocardial infarction, 
glomerulosclerosis, idiopathic pulmonary fibrosis, liver 
cirrhosis and systemic sclerosis (SSc).
In SSc, the tightly regulated and self-limited 
response to injury, normally leading to tissue regeneration, 
is subverted into fibrosis, with disruption of tissue 
architecture and loss of functional integrity; both the skin 
and the internal organs can be affected. An inappropriate 
fibroblast activation and the subsequent accumulation of 
myofibroblasts in affected tissues underlie this switch. A 
subgroup of resident fibroblasts, in response to specific 
stimuli (e.g. transforming growth factor-β), trans-
differentiate into myofibroblasts expressing high levels of 
α-smooth muscle actin (α-SMA) and playing a significant 
functional role in pathologic fibrosis [1].
N-formyl peptide (fMLF) receptors (FPRs) are a 
family of pattern recognition receptors, regulating innate 
responses. FPRs, by interacting with several structurally 
diverse pro- and anti-inflammatory ligands, possess 
important regulatory effects in multiple pathological 
conditions, including inflammation and cancer. In addition, 
all FPRs expressed on epithelia seem to be required 
for wound repair and restitution of barrier integrity, by 
facilitating epithelial cell migration, proliferation, and 
neo-angiogenesis [2]. 
Three variants of FPRs have been identified in 
humans: FPR1, FPR2, and FPR3. FPR1 is activated by 
nanomolar concentrations of fMLF. FPR2 is a promiscuous 
receptor activated in response to high concentrations of 
fMLF, and to viral, bacterial, endogenous and synthetic 
peptides. Hp(2-20), uPAR84-95, and F2L are natural ligands 
of FPR3. The synthetic peptide WKYMVm is an FPR 
panagonist, depending on its concentration [3]. 
Several functions of FPRs occur through the 
interaction with the urokinase-type plasminogen activator 
(uPA) receptor (uPAR). uPAR is formed by three 
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Panel A: normal fibroblasts. After stimulation of FPRs/uPAR cross-talk by ATF, unmasking the uPAR
88-92
 region, or FPRs engagement 
by WKYMVm and uPAR84-95 peptides,  migration and proliferation increase and a myofibroblastic phenotype is acquired, through increased 
α-SMA expression, matrix deposition and ROS generation.
Panel B: SSc fibroblasts. Membrane expression of FPRs and of a truncated uPAR form (DII-DIII-uPAR
88–92
), originating by uPA- or 
protease-mediated uPAR cleavage, is increased. DII-DIII-uPAR
88–92 
contains the SRSRY peptide that, by chronically interacting with FPRs, 
could desensitize them to migratory and proliferative signals. FPRs stimulation by WKYMVm and uPAR84-95 peptides is still able to induce 
matrix deposition and ROS generation.
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homologous domains (DI, DII, DIII) anchored to the 
cell surface by a glycosyl-phosphatidylinositol (GPI) tail 
and is able to interact with integrins, FPRs and tyrosine 
kinase receptors, representing a main regulator of signal 
transduction pathways involved in wound repair, tumor 
progression and angiogenesis [4]. A specific region of 
uPAR, corresponding to amino acids 88-92 (SRSRY), 
located in the flexible linker connecting uPAR domains 
DI and DII, is able to interact with FPRs, mediating uPA 
or fMLF-dependent cell migration. Indeed, the uPAR-
derived, synthetic uPAR84-95 peptide can act as a direct 
ligand of FPRs. uPA or its aminoterminal fragment (ATF) 
can promote uPAR interaction with FPRs, by determining 
the exposure of the uPAR
88-92
 region, upon binding to the 
receptor. Further, uPA-mediated removal of DI results in 
the membrane expression of a truncated uPAR form, that 
can contain the chemotactic peptide able to interact with 
FPRs and to regulate their signal (DII-DIII-uPAR
88-92
) [5].
Recently, to test the possibility of FPRs being 
involved in the pathogenesis of SSc, we investigated 
whether FPRs were expressed on human skin fibroblasts 
and whether their activation could play a role in some as 
yet unexplained processes involved in SSc, such as wound 
healing, tissue remodeling and fibrosis. We provided 
evidence, for the first time, that FPRs are expressed by 
normal human skin fibroblasts and that SSc fibroblasts 
overexpress these receptors both in vitro and in vivo [6].
FPRs could be involved in the pathogenesis of SSc 
through different mechanisms, including the interaction 
with the uPA/uPAR system. Indeed, we showed that 
activation of FPRs by the WKYMVm peptide and 
stimulation of FPRs/uPAR cross-talk by ATF and uPAR84-
95 peptide increased proliferation and migration of normal 
fibroblasts and could induce a myofibroblastic phenotype, 
as shown by increased matrix deposition, αvβ5 integrin 
and α-SMA expression and Radical Oxygen Species 
(ROS) generation. This supports the hypothesis that the 
SSc progressive fibrosis could be linked to the aberrant 
activation of FPRs signalling in fibroblasts. 
uPAR deletion induces, in a murine model, 
pulmonary fibrosis and peripheral microvasculopathy 
resembling human SSc. Full-length uPAR expression is 
significantly downregulated in SSc dermis, especially in 
fibroblasts and endothelial cells [7]. We demonstrated that, 
in SSc fibroblasts, full length uPAR down-regulation is 
accompanied by increased membrane expression of DII-
DIII-uPAR
88-92
. SSc fibroblasts exhibited characteristics 
suggesting a myofibroblast transition, such as elevated 
levels of α-SMA expression and vitronectin secretion, 
in agreement with previous studies showing that the 
cleavage/inactivation of uPAR is a crucial step in the 
fibroblast-to-myofibroblast transition [8]. 
We suggest that, in normal fibroblasts, innate 
immune signaling triggered by FPRs ligands is one 
of the key events converting self-limited regenerative 
repair into an aberrant and intractable fibrotic process, 
by determining increased proliferation, migration and 
fibroblast to myofibroblast transition. SSc fibroblasts, 
showing myofibroblastic features, overexpress FPRs 
but their proliferative and migratory signals are strongly 
reduced. Thus, a condition of receptor inactivation occurs, 
most probably through the increased membrane expression 
of DII-DIII-uPAR
88-92
 that, by chronically interacting with 
FPRs, could desensitize them. Stimulation of FPRs did 
not increase further α-SMA expression in SSc fibroblasts; 
however, their signalling was still able to promote matrix 
deposition, αvβ5 integrin expression and ROS generation. 
The capacity of FPRs, through their interaction 
with the uPA/uPAR system, to trigger the transformation 
of fibroblasts into myofibroblasts and to coordinate 
proliferation and cell migration makes them a potential 
novel therapeutic target in the treatment of early SSc.
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